Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Stopped early · Phase 3

Conditions studied: Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain

In brief

The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.

Key facts

Study ID

NCT00060996

Run by

United Therapeutics

People needed

30

Starts

2003-02-01

Expected to finish

2004-09-01

Last updated by the study team

2013-03-07

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of South Florida College of Medicine — Tampa, Florida, United States
• University of Massachusetts Memorial Health — Worcester, Massachusetts, United States
• Minneapolis Heart Institute — Minneapolis, Minnesota, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• Presbyterian Medical Center, Philadelphia Heart Institute — Philadelphia, Pennsylvania, United States
• South Carolina Heart Center — Columbia, South Carolina, United States
• The Methodist Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.